• Psoriasis

Ilumya Generic Name & Formulations

General Description

Tildrakizumab-asmn 100mg/mL; soln for SC inj; preservative-free.

Pharmacological Class

Interleukin-23 antagonist.

How Supplied

Single-dose prefilled syringe—1 (w. needle guard + cover)

Generic Availability


Ilumya Indications


Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Ilumya Dosage and Administration


Give by SC inj in abdomen, thighs, or upper arm. ≥18yrs: 100mg at Weeks 0 and 4, then every 12 weeks thereafter.


<18yrs: not established.

Ilumya Contraindications

Not Applicable

Ilumya Boxed Warnings

Not Applicable

Ilumya Warnings/Precautions


Should only be administered by a healthcare provider. Discontinue if serious hypersensitivity reaction occurs; treat appropriately. May increase risk of infections. Chronic or history of recurrent infection: consider the risks and benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for tuberculosis (TB) infection prior to initiating. History of latent or active TB (without confirmed adequate treatment); consider anti-TB therapy prior to initiation. Monitor for signs/symptoms of active TB during and after therapy. Patients with active TB infection: do not initiate. Consider completion of all age appropriate immunizations according to current guidelines before starting therapy. Pregnancy. Nursing mothers.

Ilumya Pharmacokinetics

See Literature

Ilumya Interactions


Concomitant live vaccines: not recommended.

Ilumya Adverse Reactions

Adverse Reactions

Upper respiratory infections, inj site reactions, diarrhea; hypersensitivity reactions.

Ilumya Clinical Trials

See Literature

Ilumya Note

Not Applicable

Ilumya Patient Counseling

See Literature